TWST has been the subject of several other research reports. Evercore ISI initiated coverage on Twist Bioscience in a report on Friday, February 7th. They issued a buy rating and a $42.00 price objective for the company. Cowen reissued a buy rating on shares of Twist Bioscience in a report on Monday, February 3rd. Finally, ValuEngine cut Twist Bioscience from a hold rating to a sell rating in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Twist Bioscience presently has an average rating of Hold and an average price target of $34.50.
Twist Bioscience stock opened at $30.20 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.03 and a current ratio of 5.28. The business’s 50-day simple moving average is $24.12 and its two-hundred day simple moving average is $25.37. The company has a market cap of $1.07 billion, a PE ratio of -6.71 and a beta of 0.63. Twist Bioscience has a fifty-two week low of $20.05 and a fifty-two week high of $35.95.
In other Twist Bioscience news, COO Patrick Weiss sold 4,089 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $22.29, for a total transaction of $91,143.81. Following the completion of the sale, the chief operating officer now directly owns 95,628 shares in the company, valued at approximately $2,131,548.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Patrick John Finn sold 36,932 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $23.83, for a total value of $880,089.56. Over the last quarter, insiders have sold 89,791 shares of company stock valued at $2,128,161. 25.10% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of TWST. Vanguard Group Inc. grew its position in shares of Twist Bioscience by 321.8% in the second quarter. Vanguard Group Inc. now owns 1,055,474 shares of the company’s stock valued at $30,619,000 after purchasing an additional 805,251 shares in the last quarter. State Street Corp grew its position in shares of Twist Bioscience by 1.9% in the fourth quarter. State Street Corp now owns 889,047 shares of the company’s stock valued at $18,670,000 after purchasing an additional 16,400 shares in the last quarter. Millennium Management LLC grew its position in shares of Twist Bioscience by 7,776.1% in the third quarter. Millennium Management LLC now owns 847,079 shares of the company’s stock valued at $20,228,000 after purchasing an additional 836,324 shares in the last quarter. Lord Abbett & CO. LLC grew its position in shares of Twist Bioscience by 15.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 555,167 shares of the company’s stock valued at $11,659,000 after purchasing an additional 75,706 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $10,207,000. Institutional investors own 47.32% of the company’s stock.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
Further Reading: Treasury Bonds
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.